These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 36163662)

  • 1. Community- vs. hospital-based management of multidrug-resistant TB in Pakistan.
    Fatima R; Yaqoob A; Qadeer E; Khan MA; Ghafoor A; Jamil B; Haq MU; Ahmed N; Baig S; Rehman A; Abbasi Q; Khan AW; Ikram A; Hicks JP; Walley J
    Int J Tuberc Lung Dis; 2022 Oct; 26(10):929-933. PubMed ID: 36163662
    [No Abstract]   [Full Text] [Related]  

  • 2. Occurrence of adverse events in patient receiving community-based therapy for multidrug-resistant tuberculosis in Pakistan.
    Javaid A; Khan MA; Jan F; Rauf M; Khan MA; Basit A; Mehreen S
    Tuberk Toraks; 2018 Mar; 66(1):16-25. PubMed ID: 30020037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients.
    Atif M; Bashir A; Ahmad N; Fatima RK; Saba S; Scahill S
    BMC Infect Dis; 2017 Sep; 17(1):655. PubMed ID: 28962599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa.
    Loveday M; Wallengren K; Brust J; Roberts J; Voce A; Margot B; Ngozo J; Master I; Cassell G; Padayatchi N
    Int J Tuberc Lung Dis; 2015 Feb; 19(2):163-71. PubMed ID: 25574914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and treatment outcomes of patients with multi-drug resistant tuberculosis at a tertiary care hospital in Peshawar, Pakistan.
    Khan MA; Mehreen S; Basit A; Khan RA; Jan F; Ullah I; Ihtesham M; Khan A; Ullah U; Javaid A
    Saudi Med J; 2015 Dec; 36(12):1463-71. PubMed ID: 26620989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.
    Naz F; Ahmad N; Wahid A; Ahmad I; Khan A; Abubakar M; Khan SA; Khan A; Latif A; Ghafoor A
    BMC Infect Dis; 2021 Dec; 21(1):1209. PubMed ID: 34863099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.
    Ahmad N; Javaid A; Syed Sulaiman SA; Afridi AK; Zainab ; Khan AH
    Am J Ther; 2018; 25(5):e533-e540. PubMed ID: 26938643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcomes among multidrug-resistant TB patients in Bahawal Victoria Hospital, Bahawalpur, Pakistan: a retrospective record review.
    Atif M; Ahmad W; Ahmad N; Malik I; Sarwar S
    Trans R Soc Trop Med Hyg; 2020 Oct; 114(10):733-741. PubMed ID: 32556195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pattern of Drug Resistance and Risk Factors Associated with Development of Drug Resistant Mycobacterium tuberculosis in Pakistan.
    Ullah I; Javaid A; Tahir Z; Ullah O; Shah AA; Hasan F; Ayub N
    PLoS One; 2016; 11(1):e0147529. PubMed ID: 26809127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-evaluating the merits of decentralization as a core strategy for effective delivery of drug-resistant tuberculosis care in Pakistan.
    Khan U; Lotia-Farrukh I; Akhtar A; Khowaja SN; Khan S; Madhani F; Parekh A; Adnan S; Ahmed S; Chaudhry M; Hussain H; Habib A; Butt S; Siddiqui MR; Ijaz R; Jamal S; Khan AB; Keshavjee S; Khan AJ; Salahuddin N; Khan PY
    Health Policy Plan; 2022 Sep; 37(8):979-989. PubMed ID: 35527232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of treatment outcomes and factors associated with unsuccessful outcomes in multidrug resistant tuberculosis patients in Baluchistan province of Pakistan.
    Khan I; Ahmad N; Khan S; Muhammad S; Ahmad Khan S; Ahmad I; Khan A; Gulalai ; Atif M
    J Infect Public Health; 2019; 12(6):809-815. PubMed ID: 31056438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa.
    Schnippel K; Rosen S; Shearer K; Martinson N; Long L; Sanne I; Variava E
    Trop Med Int Health; 2013 Jan; 18(1):109-16. PubMed ID: 23170876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management and treatment outcomes of MDR-TB: results from a setting with high rates of drug resistance.
    Ahmad N; Javaid A; Basit A; Afridi AK; Khan MA; Ahmad I; Sulaiman SA; Khan AH
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1109-14, i-ii. PubMed ID: 26260834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Project extension for community healthcare outcomes improves care and treatment for multidrug-resistant tuberculosis patients in Tanzania.
    Peter DD; Mziray SR; Lekule IA; Kitundu V; Mohamed S; Kisonga RM; Mpagama SG; Struminger BB
    Int J Mycobacteriol; 2021; 10(2):182-187. PubMed ID: 34558472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of poor treatment outcomes in multidrug-resistant tuberculosis patients: a retrospective cohort study.
    Javaid A; Ullah I; Masud H; Basit A; Ahmad W; Butt ZA; Qasim M
    Clin Microbiol Infect; 2018 Jun; 24(6):612-617. PubMed ID: 28970158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors related to previous tuberculosis treatment of patients with multidrug-resistant tuberculosis in Bangladesh.
    Rifat M; Hall J; Oldmeadow C; Husain A; Hinderaker SG; Milton AH
    BMJ Open; 2015 Sep; 5(9):e008273. PubMed ID: 26351185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience.
    Liu CH; Li L; Chen Z; Wang Q; Hu YL; Zhu B; Woo PC
    PLoS One; 2011 Apr; 6(4):e19399. PubMed ID: 21559362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A qualitative evaluation of hospital versus community-based management of patients on injectable treatments for tuberculosis.
    Cohen DB; Phiri M; Banda H; Squire SB; Namakhoma I; Desmond N
    BMC Public Health; 2018 Sep; 18(1):1127. PubMed ID: 30223808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.